Allergies News and Research

Latest Allergies News and Research

Shire announces acquisition of Meritage Pharma

Shire plc and Meritage Pharma, Inc. announced today that Shire has acquired Meritage, a privately-held company, for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.

24 Feb 2015

Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.

24 Feb 2015

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas.

24 Feb 2015

Henry Ford researchers say that breastfeeding influences baby's immune system development

Henry Ford Hospital researchers say that breastfeeding and other factors influence a baby's immune system development and susceptibility to allergies and asthma by what's in their gut.

23 Feb 2015

Epigenome-wide association study helps discover genes linked to allergies and asthma

Researchers from Canada, the UK, Sweden and the US have discovered more than 30 genes that strongly affect an antibody involved in allergies and asthma. Some of the genes could provide targets for drugs to treat those conditions, according to the international team's study, published online in Nature on Feb. 18.

20 Feb 2015

New study turns to epigenetics to look for new therapeutic targets to treat allergic diseases

Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.

20 Feb 2015

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

Data have been presented today on the use of Hospira’s Inflectra (infliximab), the world’s first approved biosimilar monoclonal antibody (mAb), at the European Crohn’s and Colitis Organisation Inflammatory Bowel Diseases (ECCO-ibd) conference.

19 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

A drug used to treat patients with Crohn's disease and multiple sclerosis has helped scientists confirm how "viral reservoirs" form in patients living with HIV and also proven effective in animal trials at blocking the pathways to those reservoirs in the brain and gut, a team of researchers reported recently in the journal PLOS Pathogens.

19 Feb 2015

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Two new clinical trials are examining the safety and acceptability of antiretroviral medicines administered via injection as a means of protecting against HIV infection. The studies are being funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and conducted by the NIAID-funded HIV Prevention Trials Network (HPTN).

19 Feb 2015

Study findings could lead to new potential drug targets for allergic diseases

Scientists have discovered over 30 new genes that predispose people to allergies and asthma, some of which could be targets for new drugs.

19 Feb 2015

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is expanding its Tuberculosis Research Units program in an effort to drive innovation in tuberculosis (TB) research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.

19 Feb 2015

Weill Cornell receives NIH grant to study TB-causing bacteria

In an effort to stop tuberculosis (TB) from becoming progressively less treatable worldwide, the National Institutes of Health has awarded Weill Cornell Medical College more than $6.2 million in first-year funding to support a research collaboration among six institutions in close alliance with voluntary pharmaceutical partners.

19 Feb 2015

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

Scientists have created a new molecule that shows promise for controlling HIV without daily antiretroviral drugs. The molecule foils a wider range of HIV strains in the laboratory than any known broadly neutralizing HIV antibody and is more powerful than some of the most potent of these antibodies.

19 Feb 2015

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

A clinical trial called HVTN 100 has been launched in South Africa to study an investigational HIV vaccine regimen for safety and the immune responses it generates in study participants. This experimental vaccine regimen is based on the one tested in the U.S. Military HIV Research Program-led RV144 clinical trial in Thailand--the first study to demonstrate that a vaccine can protect people from HIV infection.

19 Feb 2015

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.

16 Feb 2015

Study: Ebola transmission from deceased patients may be possible

To determine how long Ebola virus could remain infectious in a body after death, National Institutes of Health scientists sampled deceased Ebola-infected monkeys and discovered the virus remained viable for at least seven days. They also detected non-infectious viral RNA for up to 70 days post-mortem. The study, published in Emerging Infectious Diseases, suggests that Ebola transmission from deceased individuals may be possible for an extended period of time following death, underscoring the importance of using safe practices for handling corpses.

15 Feb 2015

Diabetes medication can help white blood cells fight bacterial infections

Pioglitazone, a medication approved for treatment of type 2 diabetes, can help bypass genetic defects in chronic granulomatous disease to help white blood cells fight bacterial infections, according to researchers at National Jewish Health.

12 Feb 2015

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients’ health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

Bayer offers wide range of material solutions for OEMs' medical application needs

Increasingly, innovative medical applications place further importance on the success of the materials they use. When patients' health, mobility and comfort are involved, reliability and durability are crucial. Bayer MaterialScience LLC steps up to the challenge offering original equipment manufacturers (OEMs) a wide range of material solutions for their medical application needs.

10 Feb 2015

Allergies News and Research

Latest Allergies News and Research

Shire announces acquisition of Meritage Pharma

Peanut consumption in infancy prevents allergy in kids who are at high-risk for developing peanut allergy

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Henry Ford researchers say that breastfeeding influences baby's immune system development

Epigenome-wide association study helps discover genes linked to allergies and asthma

New study turns to epigenetics to look for new therapeutic targets to treat allergic diseases

InflectraTM (infliximab) patient registry reports interim results in the treatment of inflammatory bowel disease

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

Natalizumab drug helps scientists confirm how 'viral reservoirs' form in HIV patients

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

Study findings could lead to new potential drug targets for allergic diseases

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

Weill Cornell receives NIH grant to study TB-causing bacteria

New molecule shows promise in controlling HIV without using daily antiretroviral drugs

New clinical trial launched in South Africa to study investigational HIV vaccine regimen

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Study: Ebola transmission from deceased patients may be possible

Diabetes medication can help white blood cells fight bacterial infections

Bayer materials withstand demanding conditions and meet requirements for innovative medical devices MD&M West

Bayer offers wide range of material solutions for OEMs' medical application needs

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Allergies News and Research

Latest Allergies News and Research

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in